Meeting
2021 ASCO Annual Meeting
A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports.
Authors
Jing Jin
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Jing Jin , Yuan Tang , Chen Hu , Yong Cai , Yuan Zhu , Guanghui Cheng , Hongyan Zhang , Xin Wang , Suyu Zhu , Jun Wang , Gaofeng Li , Jialin Yang , Kuan Zhang , Yihebali Chi , Haitao Zhou , Lichun Wei , Wenling Wang , Shixin Liu , Yuanhong Gao , Ye-Xiong Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT00833131
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3510)
DOI
10.1200/JCO.2021.39.15_suppl.3510
Abstract #
3510
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe
Poster
2021 ASCO Annual Meeting
Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.
First Author: Ji Zhu
Poster
2013 ASCO Annual Meeting
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.
First Author: Hans-Joachim Schmoll
Poster
2023 ASCO Annual Meeting
Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).
First Author: Zhenyu Lin